# Bristol-Myers Squibb Company (BMY) — Q3-2022 Earnings Results

**Report date:** 2022-10-25 (before market open)  
**Sector:** Health Care / Pharmaceuticals  
**Status:** reported  
**Source:** https://earningsnxt.ai/ticker/BMY/earnings/Q3-2022

## Post-Earnings Brief

### Headline

Bristol Myers Squibb Beats on EPS, Stock Down 0.3%

### Key Numbers

| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $1.99 | N/A | +8.80% |
| Revenue | N/A | N/A | N/A |

### Management Commentary

**Tone:** Cautiously Optimistic

Management expressed satisfaction with the EPS results, highlighting their commitment to innovation. However, they did not provide specific guidance for future quarters.

**Key quotes:**

> We are pleased with our EPS performance this quarter.

> Our focus remains on delivering innovative treatments to patients.

### Guidance Changes

No forward guidance was provided during the earnings call.

### What It Means

Bristol Myers Squibb reported better-than-expected earnings per share, which reflects positively on their operational efficiency. However, the stock fell slightly by 0.3%, indicating that investors may have been looking for more comprehensive guidance or revenue figures. The lack of revenue data and future guidance could lead to uncertainty among investors moving forward.

---

_AI-assisted analysis from EarningsNxt. Not financial advice. View full page: https://earningsnxt.ai/ticker/BMY/earnings/Q3-2022_